HomeCompareECMXF vs JNJ

ECMXF vs JNJ: Dividend Comparison 2026

ECMXF yields 76923.08% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ECMXF wins by $3.5207463509675137e+25M in total portfolio value
10 years
ECMXF
ECMXF
● Live price
76923.08%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.5207463509675137e+25M
Annual income
$35,117,657,238,443,270,000,000,000,000,000.00
Full ECMXF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — ECMXF vs JNJ

📍 ECMXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodECMXFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ECMXF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ECMXF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ECMXF
Annual income on $10K today (after 15% tax)
$6,538,461.54/yr
After 10yr DRIP, annual income (after tax)
$29,850,008,652,676,780,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, ECMXF beats the other by $29,850,008,652,676,780,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ECMXF + JNJ for your $10,000?

ECMXF: 50%JNJ: 50%
100% JNJ50/50100% ECMXF
Portfolio after 10yr
$1.7603731754837569e+25M
Annual income
$17,558,828,619,221,635,000,000,000,000,000.00/yr
Blended yield
99.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ECMXF
No analyst data
Altman Z
-1.4
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ECMXF buys
0
JNJ buys
0
No recent congressional trades found for ECMXF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricECMXFJNJ
Forward yield76923.08%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$3.5207463509675137e+25M$30.3K
Annual income after 10y$35,117,657,238,443,270,000,000,000,000,000.00$4,689.40
Total dividends collected$3.520157521397876e+25M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ECMXF vs JNJ ($10,000, DRIP)

YearECMXF PortfolioECMXF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$7,703,008$7,692,307.69$10,592$272.30+$7.69MECMXF
2$5,545,990,379$5,537,748,161.26$11,289$357.73+$5545.98MECMXF
3$3,732,151,735,917$3,726,217,526,211.36$12,123$472.89+$3732151.72MECMXF
4$2,347,491,508,714,269$2,343,498,106,356,837.00$13,141$629.86+$2347491508.70MECMXF
5$1,380,119,533,083,814,100$1,377,607,717,169,489,700.00$14,408$846.81+$1380119533083.80MECMXF
6$758,404,537,995,947,800,000$756,927,810,095,548,100,000.00$16,021$1,151.60+$758404537995947.75MECMXF
7$389,547,620,856,236,000,000,000$388,736,128,000,580,400,000,000.00$18,122$1,588.22+$389547620856236032.00MECMXF
8$187,025,031,600,452,680,000,000,000$186,608,215,646,136,520,000,000,000.00$20,930$2,228.20+$187025031600452665344.00MECMXF
9$83,931,094,609,218,200,000,000,000,000$83,730,977,825,405,720,000,000,000,000.00$24,792$3,191.91+$8.39310946092182e+22MECMXF
10$35,207,463,509,675,137,000,000,000,000,000$35,117,657,238,443,270,000,000,000,000,000.00$30,274$4,689.40+$3.5207463509675137e+25MECMXF

ECMXF vs JNJ: Complete Analysis 2026

ECMXFStock

Universal Copper Ltd., an exploration stage company, engages in the acquisition, exploration, and development of copper properties in Canada. The company holds interests in the Poplar property, which covers an area of 65,817 hectares located in the Omineca mining division, British Columbia; the Princeton project located in British Columbia; and the Copper Mountain property located in Canada. It has an option to acquire 100% interest in the Lac Villebon property consisting of 15 mining claims covering 864 hectares located in Lac Villebon Township; and the Palermo property consisting of 6 mining claims covering an area of approximately 240 hectares located in Hebecourt Township. The company was formerly known as Tasca Resources Ltd. and changed its name to Universal Copper Ltd. in March 2019. Universal Copper Ltd. was incorporated in 1997 and is headquartered in Vancouver, Canada.

Full ECMXF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ECMXF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ECMXF vs SCHDECMXF vs JEPIECMXF vs OECMXF vs KOECMXF vs MAINECMXF vs ABBVECMXF vs MRKECMXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.